TY - JOUR
T1 - Primary breast diffuse large B-cell lymphoma
T2 - treatment strategies and patterns of failure*
AU - Ludmir, Ethan B.
AU - Milgrom, Sarah A.
AU - Pinnix, Chelsea C.
AU - Gunther, Jillian R.
AU - Westin, Jason
AU - Oki, Yasuhiro
AU - Fayad, Luis E.
AU - Medeiros, L. Jeffrey
AU - Dabaja, Bouthaina S.
AU - Nastoupil, Loretta J.
N1 - Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and central nervous system prophylaxis (CNS PPX). Fifty-two percent of patients received RT, and 28% received CNS PPX. Fourteen patients (56%) experienced recurrence, with 76% of relapses occurring ≥24 months after diagnosis, in contrast to reports supporting the use of 24-month event-free survival as a surrogate endpoint in the general DLBCL population. Use of RT was associated with a trend toward improved progression-free survival (PFS). Twenty percent of patients experienced CNS relapse, with no clear benefit to CNS PPX. These data emphasize the importance of long-term follow-up for PB-DLBCL patients, suggest a PFS benefit with the addition of RT, and highlight high rates of CNS relapse.
AB - Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and central nervous system prophylaxis (CNS PPX). Fifty-two percent of patients received RT, and 28% received CNS PPX. Fourteen patients (56%) experienced recurrence, with 76% of relapses occurring ≥24 months after diagnosis, in contrast to reports supporting the use of 24-month event-free survival as a surrogate endpoint in the general DLBCL population. Use of RT was associated with a trend toward improved progression-free survival (PFS). Twenty percent of patients experienced CNS relapse, with no clear benefit to CNS PPX. These data emphasize the importance of long-term follow-up for PB-DLBCL patients, suggest a PFS benefit with the addition of RT, and highlight high rates of CNS relapse.
KW - Diffuse large B-cell lymphoma
KW - breast cancer
KW - intrathecal chemotherapy
KW - lymphoma
KW - radiotherapy
KW - survivorship
UR - http://www.scopus.com/inward/record.url?scp=85046010279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046010279&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1460825
DO - 10.1080/10428194.2018.1460825
M3 - Article
C2 - 29697005
AN - SCOPUS:85046010279
SN - 1042-8194
VL - 59
SP - 2896
EP - 2903
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -